If this kind of company isn't your style, you like companies that generate revenue, and even earn profits, then you may well be interested in Exelon (NASDAQ:EXC). While this doesn't necessarily ...

OpenAI’s big rebranding effort brings a new logo and a new typeface, OpenAI sans. OpenAI’s big rebranding effort brings a new logo and a new typeface, OpenAI sans. Emma Roth is a news writer ...

BMO Capital raised the firm’s price target on Exelon (EXC) to $46 from $44 and keeps an Outperform rating on the shares ahead of its Q4 results. The firm expects a robust capital plan update ...

After parting ways with BeiGene in 2023, Novartis effectively bowed out of the PD-1 race. Now, the rising class of bispecifics opened up an opportunity for the Swiss pharma to reenter the space ...

2. Please see detailed guidance assumptions on page 7. 3. As defined on page 35 of the Condensed Financial Report, Continuing operations include the retained business activities of Novartis, ...

Mumbai: In a fresh challenge to Novartis' blockbuster heart failure drug Entresto, Indian generics maker Lupin has received approval from the U.S. Food and Drug Administration (FDA) for its generic ...

2024--Exelon Corp. (Nasdaq: EXC) announced today that it is consolidating the executive leadership team, with Gayle Littleton stepping down as Executive Vice President, Chief Legal Officer and ...

But Steinfeld is gearing up for another arena. Steinfeld is teaming up with pharmaceutical company Novartis to raise awareness about breast cancer with a bold and empowering commercial that will ...

To direct more attention toward the importance of regular breast cancer screenings, Novartis is taking to one of television’s biggest stages. The drugmaker’s first-ever Super Bowl ad is set to ...

28 release. Existing investor F-Prime Capital also joined the round, with participation from new investors Novartis Venture Fund, RiverVest Venture Partners, funds managed by abrdn, Pictet ...